|
Orthologous residues
|
|
CDK2 (human): T160‑p, CDK2 (mouse): T160‑p, CDK2 (rat): T160‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody
|
|
Relevant cell lines - cell types - tissues:
C2C12 (myoblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
neuregulin
|
|
|
|
increase
|
|
|
AG1478
|
neuregulin
|
|
|
inhibit treatment-induced increase
|
|
|
PD98059
|
neuregulin
|
|
|
inhibit treatment-induced increase
|
|
|
LY294002
|
neuregulin
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
enzymatic activity, induced
|
